⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3097743 | 0.77 | SLC1A2 (0.37) | — | |
| SCHEMBL6129550 | 0.77 | — | — | |
| SCHEMBL6129575 | 0.77 | — | — | |
| SCHEMBL1332932 | 0.77 | — | — | |
| SCHEMBL16667373 | 0.75 | TP53 (0.38) | — | |
| SCHEMBL16667376 | 0.75 | TP53 (0.38) | — | |
| SCHEMBL1406004 | 0.75 | TP53 (0.38) | — | |
| SCHEMBL199977 | 0.75 | TP53 (0.38) | — | |
| SCHEMBL1406003 | 0.75 | TP53 (0.38) | — | |
| Ammonia Solution, Strong SCHEMBL6062292 | 0.74 | SLC1A2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023175346-A1 | METHOD OF DETERMINING THE ENANTIOMERIC PURITY OF AN ANALYTE USING ION MOBILITY SPECTROMETRY | MICROMASS UK LIMITED (GB) | 2023-09-21 | — | — | WO | disclosed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11590158-B2 | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same | NOVARTIS AG (CH) | 2023-02-28 | — | — | US | disclosed |
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11230536-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210393671-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | NOVARTIS PHARMA AG (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11135239-B1 | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same | NOVARTIS AG (CH) | 2021-10-05 | — | — | US | disclosed |
| US-20210283171-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | NOVARTIS PHARMA AG (CH) | 2021-09-16 | — | — | US | disclosed |
| WO-2016133803-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160228395-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-11 | — | — | US | disclosed |
| US-20130079309-A1 | Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-03-28 | — | — | US | disclosed |
| US-8318787-B2 | Prodrugs of (3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-C]oxazol-7A-yl)methanol and derivatives thereof | UNIVERSITY OF KANSAS (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2011109650-A1 | METHOD OF TREATING ACUTE LUNG INJURY USING SPHINGOSINE 1 PHOSPHATE ANALOGES OR SPHINGOSINE 1 PHOSPHATE RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20100056592-A1 | PRODRUGS OF (3,5-BIS(4-FLUOROPHENYL)TETRAHYDRO-1H-OXAZOLO[3,4-C]OXAZOL-7A-YL)METHANOL AND DERIVATIVES THEREOF | UNIVERSITY OF KANSAS | 2010-03-04 | — | — | US | disclosed |
| US-7598282-B2 | (3R,5S,7as)-(3,5-bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol; does not involve microtubule stabilization; Alzheimer's | UNIVERSITY OF KANSAS (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2007053684-A2 | NEUROPROTECTIVE AGENTS | UNIVERSITY OF KANSAS (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099971-A1 | Neuroprotective agents | UNIVERSITY OF KANSAS | 2007-05-03 | — | — | US | disclosed |
| US-4290972-A | Process for the production of 4-aminobutyric acid or its derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 1981-09-22 | — | — | US | disclosed |